sever
line
evid
support
role
immunolog
mechan
pathogenesi
multipl
sclerosi
ms
new
immunomodulatori
strategi
treatment
eg
subcutan
applic
interferon
ifn
b
emerg
investig
abil
peripher
blood
mononuclear
cell
pbmc
consecut
patient
clinic
definit
ms
produc
interferon
lymphokin
respons
viral
mitogen
stimul
ten
patient
show
clinic
sign
diseas
activ
acut
relaps
patient
stabl
condit
addit
white
blood
count
leukocyt
differenti
lymphocyt
subtyp
perform
group
agerel
healthi
blood
donor
serv
control
differ
patient
control
product
ifng
tumor
necrosi
factor
tnf
solubl
interleukin
il
receptor
ifna
ifnb
respons
howev
significantli
lower
patient
stabl
diseas
patient
activ
diseas
control
furthermor
secret
stimul
significantli
diminish
patient
group
compar
control
group
analysi
tcell
subset
reveal
significantli
lower
amount
tcell
patient
stabl
diseas
lead
significantli
higher
ratio
group
compar
patient
activ
diseas
studi
depict
defici
ms
patient
share
autoimmun
diseas
addit
find
suggest
abil
produc
typei
ifn
ifna
ifnb
primarili
impair
ms
patient
chang
correl
cours
diseas
activ
elsevi
scienc
b
v
tive
tlymphocyt
ms
patient
particular
usag
specif
tcell
receptor
element
recognialthough
etiolog
multipl
sclerosi
still
tion
immunodomin
region
autoantigen
unknown
consider
expans
myelin
basic
protein
wucherpfennig
et
al
lodg
et
understand
pathogenesi
diseas
process
al
other
assess
role
cytokin
last
year
poser
immunolog
peptid
glycopeptid
mediat
immun
system
mechan
cellular
humor
seem
play
cours
diseas
beck
et
al
central
role
inflammatori
process
lead
first
show
pbmc
individu
ms
patient
demyelin
destruct
oligodendrocyt
produc
increas
amount
ifng
tnfa
central
nervou
system
cn
rain
earli
stage
exacerb
diseas
thu
ing
clinic
manifest
relaps
find
studi
focus
presenc
autoreacwer
later
confirm
tnfa
mrna
level
rieckmann
et
al
tnfa
understood
play
crucial
role
upregul
adhes
molecul
involv
tcell
migrat
site
inflamm
control
group
examin
agematch
healthi
blood
hartung
et
al
furthermor
high
level
expresdonor
fulfil
criteria
german
regul
sion
proinflammatori
well
immunosuppress
whole
blood
donat
cytokin
detect
ms
lesion
postmortem
cn
tissu
mean
immunocytochemistri
cannella
leukocyt
count
lymphocyt
subset
rain
understand
role
cytokin
multipl
peripher
venou
blood
sampl
test
whole
sclerosi
becom
increasingli
import
sinc
new
blood
differenti
blood
count
mean
autotreat
strategi
multipl
sclerosi
emerg
matic
analyz
coulter
stk
flow
cytomet
lympho
mcdonald
interferon
report
cyte
subpopul
analysi
perform
flow
cytomreduc
exacerb
rate
sever
exacerb
etri
coulter
epic
xl
mcl
flow
cytomet
coulter
patient
relapsingremit
ms
ifnb
multielectron
hileah
fl
usa
follow
instruct
ple
sclerosi
studi
group
howev
report
manufactur
prepar
immunofluoresc
abil
releas
typei
interferon
upon
viral
stimul
stain
edtaanticoagul
blood
sampl
ms
patient
rare
assist
multiqprep
epic
immunolog
work
interferon
respons
pbmc
gener
shown
station
coulter
krefeld
germani
gate
monob
diminish
patient
ms
neighbour
et
al
nuclear
lymphat
cell
use
forward
side
light
salonen
et
al
amount
ifn
product
scatter
immunostain
could
correl
clinic
assess
determin
lymphocyt
diseas
activ
author
reveal
complet
normal
lation
b
lymphocyt
ifnrespons
upon
viral
stimul
ms
patient
tcell
activ
tcell
well
nk
cell
follow
tovel
et
al
haahr
et
al
altogeth
ing
antibodi
use
result
larg
inconclus
sinc
differ
method
use
ifninduct
detect
aim
studi
establish
whole
blood
antibodi
assay
order
investig
abil
ms
patient
serv
control
antibodi
obtain
differ
stage
diseas
activ
produc
interferon
coulter
lymphokin
respons
viral
mitogen
stimul
heparin
blood
drawn
vein
punctur
materi
method
patient
control
store
cultur
whole
blood
assay
within
h
collect
accord
patient
techniqu
describ
previous
kirchner
et
al
mitogen
induct
ifng
use
investig
consecut
patient
male
plant
lectin
phytohemagglutinin
pha
murex
femal
age
mean
deviat
nostik
burrough
wellcom
dartford
uk
final
fulfil
diagnost
criteria
multipl
concentr
mg
ml
ifna
ifnb
product
sclerosi
poser
et
al
eleven
patient
stimul
newcastl
diseas
viru
ndv
strain
relapsingremit
cours
ms
patient
sufferkumarov
inactiv
uvirradi
nm
ing
secondaryprogress
subtyp
patient
min
kindli
provid
r
zawatzki
german
cancer
progressiverelaps
cours
diseas
accordresearch
center
heidelberg
final
concentr
ing
standard
definit
lublin
et
al
hemagglutin
unit
ml
lipopolysaccharid
lp
patient
examin
classifi
independ
sigma
deisenhofen
frg
consist
purifi
estwo
clinic
neurologist
inform
consent
obcherichia
coli
oiii
endotoxin
use
inductain
patient
seen
acut
episod
tion
tnfa
final
concentr
mg
ml
ml
new
diseas
activ
acut
relaps
patient
whole
blood
mix
ml
cultur
medium
stabl
condit
acut
relaps
defin
serom
rpmi
mm
hepe
biochrom
berlin
signific
worsen
preexist
symptom
meagermani
supplement
mm
lglutamin
u
sure
expand
disabl
statu
scale
kurtzk
penicillin
per
ml
ml
streptomycin
per
ml
appear
new
neurolog
deficit
last
gibco
karlsruh
germani
ml
ppn
test
tube
least
h
none
patient
sign
system
greiner
nurtingen
germani
ml
appropri
infect
plasma
level
crp
macroglobulin
mitogen
solut
ad
induct
cytokin
neopterin
within
normal
limit
patient
product
neg
control
test
cytokin
treat
immunosuppress
drug
steroid
product
unstimul
cultur
tube
cover
preced
month
blood
sampl
incub
humidifi
atmospher
co
supern
harvest
h
tnfa
control
group
p
consid
ifna
ifnb
h
ifng
store
signific
frozen
assay
concentr
cytokin
supern
cell
differenti
blood
cell
count
lymphocyt
cultur
determin
mean
quantit
ensubpopul
zymelink
immunosorb
assay
elisa
ifna
addit
determin
sera
sampl
individu
differenti
blood
cell
count
show
signific
patient
elisa
kit
ifna
intraassay
varianc
differ
two
patient
group
tabl
interassay
varianc
ifng
intraassay
varianc
within
normal
rang
regard
interassay
varianc
tnfa
intraassay
varicyt
subpopul
found
significantli
lower
anc
interassay
varianc
intraassay
amount
tcell
patient
stabl
diseas
varianc
interassay
varianc
obtain
lead
significantli
higher
ratio
bio
sourc
intern
camarillo
ca
usa
patient
group
compar
ms
patient
undergo
elisa
kit
detect
intraassay
varianc
acut
exacerb
interassay
varianc
obtain
r
system
minneapoli
mn
usa
ifnb
cytokin
product
mitogen
stimul
say
varianc
interassay
varianc
medgenix
diagnost
ratingen
germani
serial
dilumeasur
ifng
tnfa
tion
sampl
standard
incub
microtit
supern
mitogenstimul
wholeblood
cultur
well
assay
perform
describ
reveal
signific
differ
cytokin
product
manufactur
protocol
color
intens
measur
patient
group
control
tabl
result
photometr
elisa
reader
antho
labtec
vitro
product
mitogen
stimulasalzburg
austria
individu
concentr
could
tion
shown
fig
interestingli
patient
group
determin
standard
curv
minim
detect
show
significantli
decreas
prodos
pg
ml
tnfa
ifna
ifng
duction
comparison
control
group
unit
ml
ifnb
respect
contrast
ndv
induc
product
ifna
show
highli
signific
differ
mean
valu
statist
two
patient
group
patient
stabl
diseas
pg
ml
produc
significantli
lower
amount
statist
analysi
perform
use
commerci
ifna
control
pg
ml
patient
avail
softwar
person
comput
spss
diseas
activ
pg
ml
influenc
age
window
spss
gmbh
softwar
munich
gersex
observ
result
shown
fig
ifna
mani
mannwhitneyu
test
use
compar
detect
sera
sampl
patient
nonparametr
distribut
data
patient
detect
ndv
induc
ifnb
secret
reveal
valu
given
deviat
tabl
cytokin
product
wholeblood
assay
ms
patient
acut
exacerb
stabl
diseas
control
fig
overal
ifnb
produc
termin
supern
pha
stimul
cell
cultur
horizont
bar
repres
mean
level
lower
amount
ifna
howev
mean
valu
patient
group
patient
stabl
diseas
u
ml
also
significantli
lower
patient
diseas
activ
u
ml
control
u
ml
cytokin
detect
supern
unstimul
cultur
present
studi
reveal
remark
decreas
product
ifna
ifnb
upon
viral
stimul
pbmc
ms
patient
stabl
diseas
impair
abil
secret
ms
patient
irrespect
diseas
activ
product
ifng
tnfa
differ
valu
observ
control
group
titer
increas
patient
group
either
addit
ms
patient
stabl
diseas
show
significantli
lower
number
tcell
previou
public
low
ifn
respons
variou
viral
antigen
occasion
describ
ms
patient
neighbour
et
al
salonen
et
al
diseas
activ
abb
et
al
show
associ
low
ifna
respons
mhc
columbia
ms
mri
analysi
group
could
allel
overrepres
ms
patient
possibl
regard
substitut
preexist
deficit
hillert
defect
ifn
respons
could
therefor
second
strike
featur
studi
defect
possibl
relat
genet
background
ms
product
ms
patient
regardless
patient
present
studi
howev
diminish
protheir
clinic
state
previou
studi
impair
duction
ifna
ifnb
exclus
observ
product
predominantli
describ
ms
ms
patient
stabl
diseas
patient
admit
patient
stabl
diseas
selmaj
et
al
hospit
acut
attack
reveal
normal
ifna
produc
activ
helper
tcell
ifnb
valu
requir
appropri
lymphocyt
function
proliferin
respons
viral
stimul
pbmc
produc
mainli
ation
smith
defect
product
therefor
ifna
small
proport
ifnb
berg
et
al
result
impair
tcell
respons
diminish
two
interferon
similar
biolog
physicoprotect
viral
infect
similar
find
chemic
properti
structur
relat
kirchner
report
varieti
autoimmun
diseas
eg
therefor
classifi
typei
interferon
diabet
mellitu
zier
et
al
roncarolo
et
al
howev
strike
homolog
within
code
sjogren
syndrom
miyasaka
et
al
also
well
flank
region
ifna
ifnb
gene
neurolog
disord
like
parkinson
locat
chromosom
human
genom
kluter
et
al
act
find
suggest
primari
deficit
typei
ifn
respons
endogen
brain
neurokin
abl
influenc
ms
patient
may
render
suscept
factor
central
nervou
function
haugen
letourneau
caus
exacerb
diseas
merril
mrna
recent
sinc
interferon
cytokin
clear
found
present
human
oligodendrocyt
otero
antivir
potenc
virus
might
respons
trig
merril
implic
role
developg
pathophysiolog
process
lead
ment
oligodendrocyt
mbp
content
reconstiexacerb
ms
one
possibl
mechan
could
tution
benvenist
merril
saneto
et
al
initi
viru
tropism
central
nervou
benvenist
et
al
system
lead
destruct
myelin
sheath
studi
cytokin
pattern
within
postmortem
cn
trigger
immun
respons
releas
autoanspecimen
howev
reveal
high
level
exprestigen
myelin
basic
protein
mbp
regard
sion
acut
mslesion
cannella
rain
coronaviru
human
current
thu
decreas
amount
supern
interest
basi
polymeras
chain
reaction
stimul
cell
cultur
could
also
result
increas
immunohistochem
studi
ms
brain
challon
et
bind
cytokin
receptor
activ
tcell
al
indic
higher
vitro
prolifer
upon
mitogen
molecular
mimicri
ie
immun
respons
stimul
ms
patient
compar
healthi
conforeign
antigen
resembl
host
protein
trol
point
mbp
specif
tcell
ms
patient
result
support
hypothesi
tcell
crossreact
peptid
divers
viral
agent
richert
mediat
suppressor
function
lost
ms
et
al
wucherpfennig
stroming
attack
recov
remiss
antel
et
al
clinic
observ
viral
infect
freinterestingli
find
signific
differ
quentli
associ
follow
acut
ms
relaps
product
tnfa
ifng
two
also
suggest
activ
peripher
immun
patient
group
crosssect
studi
sinc
ifng
compart
may
contribut
acceler
diseas
produc
activ
tlymphocyt
progress
sibley
et
al
panitch
interestth
impair
product
may
implic
select
ingli
acyclovir
antivir
drug
recent
inhibitori
mechan
may
downregul
report
significantli
reduc
exacerb
rate
ms
ifng
secret
tcell
subpopul
ms
pa
lyck
et
al
tient
howev
involv
nkcell
known
question
aris
howev
caus
typei
produc
exclud
ifn
low
respons
ms
patient
investig
cn
specimen
ms
patient
cannelmechan
involv
upregul
ifna
ifnb
la
rain
found
high
express
tnfa
gene
express
cours
relaps
serial
studi
acut
chronic
plaqu
thu
stress
role
individu
patient
requir
reveal
typei
ifn
pathogenesi
diseas
studi
howev
tnfproduct
increas
begin
attack
mainli
produc
microgli
cell
foami
lead
remiss
posit
effect
treatment
macrophag
within
lesion
ie
cell
ifnb
ifna
durelli
et
al
ifnb
multipl
detect
peripher
blood
sclerosi
studi
group
univers
british
conclus
found
abnorm
ifna
hartung
hp
reiner
k
archelo
jj
michel
seeldray
p
heidenreich
f
pflughaupt
kw
toyka
k
v
circul
activ
abil
produc
etiolog
adhes
molecul
tumor
necrosi
factor
receptor
multipl
immunolog
deficit
unknown
conclud
sclerosi
correl
magnet
reson
imag
ann
neurol
select
immunolog
abnorm
ms
patient
provid
background
diseas
suscept
haugen
pk
letourneau
pc
enhanc
chick
rat
sympathet
sensori
neurit
outgrowth
j
neurosci
progress
exacerb
possibl
trigger
divers
re
exogen
factor
eg
virus
individu
product
hillert
j
human
leukocyt
antigen
studi
multipl
sclerosi
endogen
typei
ifn
ms
patient
may
use
ann
neurol
tool
monitor
diseas
activ
studi
